AIM
HALO icon

Acrospire Investment Management’s Halozyme HALO Stock Holding History

Acrospire Investment Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100
Closed -$1K – 2316
2017
Q1 		$1K Sell
100
-4,600
-98% -$58.1K ﹤0.01% 2147
2016
Q4 		$46K Buy
+4,700
New +$51.5K 0.02% 1444
2016
Q3 		– Sell
-2,900
Closed -$25K – 2044
2016
Q2 		$25K Buy
+2,900
New +$28.6K 0.02% 1450

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's HALO Position: Q2 2017 in Review

Acrospire Investment Management sold out of Halozyme (HALO) in Q2 2017, closing a stake of 100 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in HALO in Q2 2016 and held it in 3 quarters. The position peaked at $46K in Q4 2016. 167 funds tracked by Wall St. Rank hold HALO as of Q2 2017.

  • Acrospire Investment Management reported no remaining Halozyme position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 100 Halozyme shares in Q2 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Halozyme in Q2 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Halozyme position peaked at $46K in Q4 2016.
  • 167 funds tracked by Wall St. Rank held Halozyme as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.